PRIMARY OBJECTIVES:~Phase I/Part A~1. To optimize the signal-to-noise ratio in detecting intra-tumoral hyperpolarized 13C pyruvate/lactate signal using metabolic MR imaging in participants with advanced solid tumors.~Phase II/Part B~1. To determine the mean percent change from baseline in peak intra-tumoral hyperpolarized lactate-to-pyruvate ratio and pyruvate-to-lactate kinetic constant (kPL) after initiation of SOC treatment.~SECONDARY OBJECTIVES:~Phase I/Part A~To further characterize the safety profile of hyperpolarized 13C-pyruvate.~To determine the reproducibility of intra-tumoral HP lac/pyr ratio with same-day repeated dose studies.~Phase II/Part B~To study the association between clinical outcomes and the percent change from baseline in peak intra-tumoral hyperpolarized lactate-to-pyruvate ratio and kPL after initiation of SOC treatment.~To further characterize the safety profile of hyperpolarized 13C pyruvate.~To determine the reproducibility of intra-tumoral HP lac/pyr ratio with same-day repeated dose studies.~OUTLINE:~Participants will be enrolled in Part A which is the feasibility, run-in study which includes the iterative adjustment of coil design to optimize imaging parameters within the target tumor lesion(s). If the data from Part A supports further investigation, additional participants will be enrolled in Part B which is a biomarker cohort which includes participants who are planning on being treated with either standard-of-care (SOC) or investigational therapies and will be followed until discontinuation of the treatment regimen outside of this protocol.
This is a single center prospective imaging study investigating the utility of hyperpolarized 13C-pyruvate/metabolic MR imaging. The current protocol will serve as a companion imaging biomarker study paired with standard of care (SOC) therapeutics, as well as investigational therapies that participants may be scheduled to receive outside of this protocol.